Max Gelman
@MaxGelman
Followers
2K
Following
3K
Media
430
Statuses
12K
Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]
Joined May 2011
Neumora fail: First Phase 3 for depression drug is an unequivocal miss. The company is still running two other identical Phase 3 trials, @ky_lahucik has the latest. $NMRA -79% https://t.co/MFdJpOjqC9
endpoints.news
Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials for its experimental major depression drug, saying Thursday that navacapr...
0
1
1
FDA approved Vertex's "vanza triple" formulation for cystic fibrosis, and new mutations for Trikafta. Both come with boxed warnings
news.vrtx.com
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Dec....
1
1
4
Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY
BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday. https://t.co/koSAVi3xd7
8
17
117
This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming success in Phase 1b study in ulcerative colitis. @MaxGelman has the details for @endpts -
endpoints.news
A private startup from Salt Lake City aiming to develop oral antibodies says it has succeeded in an early trial, a potentially significant scientific advancement in a world where systemic ...
1
2
8
Sarepta has a long & controversial history of getting Duchenne drugs OK’d w/accelerated approval. Now it will try in more rare diseases. "We will apply that same focus and creative energy and patient-mission approach to these therapies," the CEO said. https://t.co/Eogl6UgnKh
endpoints.news
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of biobucks in recent years.
0
0
0
The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO https://t.co/lOJfkM1yLD
endpoints.news
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost...
0
19
60
RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try https://t.co/Mu5fu9v3TW
endpoints.news
As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gaining steam is a ban on direct-to-consumer pharmaceutical advertising. Both...
0
1
2
Sage reports Phase 2 failure in Huntington's disease, ends drug's development $SAGE https://t.co/X7TjhLoJIQ
endpoints.news
Sage’s final hope to turn its business around has failed, leaving the future of the once high-flying company and its postpartum depression drug uncertain.
0
0
0
NEW: Me and @RLCscienceboss took a look at how Sage's upcoming Huntington's readout could be its last, best hope at turning the ship around https://t.co/uW3JTprc5i
endpoints.news
In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery built around a class of compounds dubbed neuroster...
0
0
1
Re-upping my piece from last week on a potential FDA commissioner under an RFK Jr.-led HHS
Biotech industry worries over potential for RFK Jr. ally as FDA pick https://t.co/H6iXZYc9iJ
0
4
9
Biotech industry worries over potential for RFK Jr. ally as FDA pick https://t.co/H6iXZYc9iJ
endpoints.news
US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...
2
5
13
Two outstanding pieces by @kakape on misinformation, open-access, @ScienceMagazine
https://t.co/FD8sQQtQQ0
https://t.co/zuLeK5PWGo
science.org
A strategy pioneered during the Cold War may prevent people from believing and sharing online falsehoods
6
60
174
Hints of impatience grow with Biogen as it tries to find a bridge to growth https://t.co/u9nk7fPH8t
endpoints.news
Biogen's investors are growing restless. Wednesday's third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year guidance, and sales of its...
0
0
1
What would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm -
endpoints.news
Donald Trump's embrace of Robert F. Kennedy Jr. is forcing biotech and pharma leaders to grapple with having US life sciences policy influenced by a figure who has extensively criticized ...
1
10
7
NEW: Eli Lilly says a slightly tweaked dosing regimen of its Alzheimer's drug Kisunla can lower the rate of brain swelling side effects https://t.co/qxhguGIK32
endpoints.news
Eli Lilly presented new data illustrating how a different dosing regimen of its Alzheimer’s drug reduced the frequency of brain swelling. The results could help Lilly argue for a change ...
1
1
0
Evergreen reminder to always double check who you’re emailing before hitting send Ex-Pfizer CFO emailed CEO Albert Bourla over the weekend. The message was blank. But the “to” field included a rep for activist Starboard From @ArmstrongDrew @maxonwifi
https://t.co/Z6p5IRWcGq
endpoints.news
The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from his former CFO Frank D’Amelio. While there was no ...
1
15
43
This year’s Women in Biopharma R&D report is dedicated to Natalie Grover, who launched the project with @AmberTongPW in 2019 while they were working at Endpoints. We’re proud to continue their tradition of honoring 20 exceptional women leaders. https://t.co/g7aeAVvPGl
endpoints.news
Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie passed away earlier ...
1
9
12
FDA approves first new schizophrenia drug in decades --> drug was centerpiece of Bristol Myers Squibb's $14B buyout of Karuna $BMY https://t.co/qVx3cXvZNy
endpoints.news
The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions. The approval gives Bristol Myers a significant foothold in the...
0
1
1
The Federal Reserve cut interest rates by 50 bps. What does that mean for biotech, pharma and venture capital?
endpoints.news
The Federal Reserve made its long-anticipated interest rate cuts on Wednesday, lowering rates by a half of a percentage point. It's the first time the Fed has cut interest rates ...
0
2
6